摘要
here is abundant evidence demonstrating a strong association between cardiovascular disease (CVD) and metabolic conditions such as obesity and type 2 diabetes, as well as chronic kidney disease (CKD).Individually, these conditions are highly prevalent.According to the American Heart Association's (AHA) 2024 heart disease and stroke statistics update, CVD was responsible for nearly 20 million deaths globally in 2020. 1 In a global assessment of CKD burden, there was a 41.5% increase in mortality rates across all age groups between 1990 and 2017. 2 Additionally, diabetes affected approximately 10.5% of adults aged 20 to 79 years worldwide in 2021 (equivalent to 536.6 million people), with projections suggesting an increase to 12.2% (783.2 million people) by 2045. 3 Together, heart disease, stroke, kidney disease, and diabetes contributed to >1 million deaths (29%) in the United States in 2021 4 and have halted nearly 5 decades of declining CVD mortality rates.5 Addressing these significant public health challenges is critical, especially as new therapeutic options emerge to manage these conditions. See Article by Li et al.Epidemiologic data provide substantial evidence suggesting that the co-occurrence of ≥1 of these conditions can multiply cardiovascular health and mortality risks.Given the intricate overlapping relationship between cardiovascular, metabolic, and renal disease, the AHA presidential advisory introduced the term cardiovascular-kidney-metabolic (CKM) syndrome to describe how heart disease, kidney disease, diabetes, and obesity interact negatively, leading to poor health outcomes.5 This new concept is expected to help health care professionals stage CKM syndrome, predict its cardiovascular effects, and manage, prevent, or even reverse it throughout life, from childhood to adulthood.Evidence backing this advisory is detailed in another scientific statement.6 Together, these publications establish a framework aimed at improving CKM health comprehensively and equitably across the population.Furthermore, they have paved the way for a new cardiovascular risk calculator that incorporates CKM health considerations for the first time.7 As research continues to highlight the interconnected and mutually reinforcing relationship between CVD, CKD, and metabolic disorders, there remains debate on the extent to which these conditions converge into a syndrome, suggesting a shared underlying pathophysiology.Previously, the interplay among these conditions lacked clear parameters, complicating treatment strategies aimed at addressing the spectrum of CKM syndrome.Therefore, the AHA's presidential advisory and accompanying scientific statement aimed to